Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

New England Journal of Medicine

Volumn 370, Issue 17, 2014, Pages 1604-1614

  Zeuzem, Stefan ^a   Jacobson, Ira M ^c   Baykal, Tolga ^e   Marinho, Rui T ^g   Poordad, Fred ^h   Bourlier̀e, Marc ⁱ   Sulkowski, Mark S ^j   Wedemeyer, Heiner ^b   Tam, Edward ^k   Desmond, Paul ^l   Jensen, Donald M ^f   Di Bisceglie, Adrian M ^m   Varunok, Peter ^d   Hassanein, Tarek ⁿ   Xiong, Junyuan ^e   Pilot Matias, Tami ^e   DaSilva Tillmann, Barbara ^e   Larsen, Lois ^e   Podsadecki, Thomas ^e   Bernstein, Barry ^e  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Premier Medical Group of the Hudson Valley   (United States)

^e ABBVIE INC   (United States)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g Centro Hospitalar de Lisboa Norte   (Portugal)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ HÔPITAL SAINT JOSEPH   (France)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k Liver and Intestinal Research Centre   (Canada)

^l ST VINCENT S HOSPITAL   (Australia)

^m SAINT LOUIS UNIVERSITY   (United States)

ⁿ Southern California Research Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABT 267; ABT 333; ABT 450; ABT 450 PLUS RITONAVIR PLUS OMBITASVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DASABUVIR; HEMOGLOBIN; MESSENGER RNA; PEGINTERFERON; PLACEBO; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; EYE JAUNDICE; FATIGUE; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NECK PAIN; NEUTROPENIA; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETREATMENT; TREATMENT DURATION; VOMITING;

ADOLESCENT; ADULT; AGED; ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; RETREATMENT; RIBAVIRIN; RITONAVIR; RNA, VIRAL; SULFONAMIDES; URACIL; VIRAL LOAD; YOUNG ADULT;

EID: 84899106124     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1401561     Document Type: Article

References (24)

1. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52.
2. Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World J Gastroenterol 2013;19:6703-9.
3. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
5. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
6. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
7. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
8. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
9. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
10. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
11. Menon RM, Klein CE, Lawal AA, et al. Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir. Presented at the annual meeting of HepDART, Kohala Coast, HI, December 6-10, 2009.
12. Lawitz E, Marbury T, Campbell A, et al. 1186 Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT1)-infected treatment-naive subjects. J Hepatol 2012;56:Suppl 2:S469-S470.
13. Poordad F, Lawitz E, DeJesus E, et al. 1206 ABT-072 or ABT-333 combined with pegylated interferon/ribavirin after 3-day monotherapy in HCV genotype 1 (GT1)-infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results. J Hepatol 2012;56:Suppl 2:S478.
14. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014;370:222-32.
15. Incivek (telaprevir) film coated tablets: US prescribing information. Cambridge, MA: Vertex Pharmaceuticals (http://pi.vrtx.com/files/uspi-telaprevir. pdf).
16. Zeuzem S, Andreone P, Pol S, et al. 5 REALIZE trial final results: telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ ribavirin. J Hepatol 2011;54: Supplement 1:S3.
17. Romero AI, Lagging M, Westin J, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006;194:895-903. (Pubitemid 44454074)
18. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014;146:430-41 e6.
19. Jacobson I, Dore GJ, Foster GR, et al. 1425 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. J Hepatol 2013;58:Supplement 1:S574.
20. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;369:678-9.
21. Lok AS, Gardiner DF, Hézode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014;60:490-9.
22. Manns MP, Bourlière M, Benhamou Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011;54:1114-22.
23. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012;55:749-58.
24. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603.